A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
OBJECTIVE
We evaluated 5-year safety, efficacy and prostate volume data from BPH patients treated with finasteride or dutasteride.


METHODS
A retrospective analysis of 378 consecutive men treated with 5α-reductase inhibitor monotherapy between January 2004 and September 2009 (197 on finasteride and 211 on dutasteride) in a single clinic was performed. Efficacy assessments included International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), postvoid residual urine volume (PVR), prostate-specific antigen (PSA) and prostate volume (PV). Safety assessments included International Index of Erectile Function (IIEF) and adverse events. Patients were evaluated at 3 months, 1 year and yearly thereafter.


RESULTS
Mean age of the group was 58.7 ± 6.7 years. Maintenance of therapy at 5 years was 57.4% and 42.5% for the finasteride and dutasteride groups respectively. Changes in IPSS, Qmax, PVR, PV and PSA were similar for both groups at 5 years. The incidence of erectile dysfunction, ejaculatory dysfunction and decreased libido resulting in discontinuation from therapy was significantly (p < 0.01) higher in the dutasteride (5.1%, 2.4%, 2.7% respectively) compared with the finasteride (2.1%, 1.8%, 1.4% respectively) group. In addition, the incidence of self-reported breast tenderness and/or enlargement was significantly (p < 0.01) greater in the dutasteride (3.5%) compared with the finasteride (1.2%) group.


CONCLUSIONS
In this retrospective analysis of data from consecutive patients treated at a single clinic, both finasteride and dutasteride were effective therapies for the management of lower urinary tract symptoms. However, dutasteride resulted in significantly more sexual side effects and breast complications than finasteride.
Weill Cornell Medical College, Cornell University, New York, 10065 NY, USA. kaplans@med.cornell.edu
S A
SA
Kaplan
D E
DE
Chung
R K
RK
Lee
S
S
Scofield
A E
AE
Te
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use*; D057915:Drug Substitution; D000068538:Dutasteride; D004542:Ejaculation / Q000187:drug effects; D007172:Erectile Dysfunction / Q000139:chemically induced; D018120:Finasteride / Q000627:therapeutic use*; D006177:Gynecomastia / Q000139:chemically induced; D006801:Humans; D007989:Libido / Q000187:drug effects; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012189:Retrospective Studies
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride